Recent advances in understanding cholangiocarcinoma

Pedro Luiz Serrano Uson Junior; Mansi Arora; James M Bogenberger; Mitesh J Borad

doi:10.12703/b/9-15

Recent advances in understanding cholangiocarcinoma

Fac Rev. 2020 Nov 19:9:15. doi: 10.12703/b/9-15. eCollection 2020.

Authors

Pedro Luiz Serrano Uson Junior^{1

2}, Mansi Arora^{1

3}, James M Bogenberger^{1

3}, Mitesh J Borad^{1

3

4

5}

Affiliations

¹ Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona, USA.
² Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
³ Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, USA.
⁵ Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, Arizona, USA.

PMID: 33659947
PMCID: PMC7886064
DOI: 10.12703/b/9-15

Abstract

The definition of cholangiocarcinoma (CCA) encompasses all tumors originating in the epithelium of the bile ducts, including the intrahepatic bile ducts (ICCA) and extrahepatic bile ducts (ECCA). The incidence of ICCA and ECCA has increased in the last few decades, and molecular advances in both entities have brought understanding of their differences and allowed treatment advances aimed at personalized therapy. In this review, we discuss recent progress in the molecular landscape of CCAs, emerging treatment biomarker-guided strategies, and future insights into the management of advanced disease.

Keywords: Cholangiocarcinoma; FGFR2; IDH1; PD-1; biliary tract cancer.

Publication types

Review

Grants and funding

The authors declare that no grants were involved in supporting this work.